Responses
Clinical/translational cancer immunotherapy
Original research
Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)
Compose a Response to This Article
Other responses
No responses have been published for this article.